Policies to promote sustainable consumption: framework for a future-oriented evaluation

Governments are today developing policies to promote sustainable consumption, yet policy makers face many uncertainties about policy impacts. These include uncertainties about how policy instruments influence consumption patterns and about the impact of changes in consumption patterns on ecological, social and economic sustainability. An assessment of such impacts must account for the fact that consumer action is interlinked with the dynamic activities of other market players and the path-creating effects of technologies and systems of consumption and provision

Internal memos regarding the homosexual issue

Typed internal memos exchanged between University of Maine administrators regarding the Wilde-Stein Club and comments by an administrator that homosexuality [is] a sickness

Observed crustal uplift near the Southern Patagonian Icefield constrains improved viscoelastic Earth model

Thirty‒one GPS geodetic measurements of crustal uplift in southernmost South America determined extraordinarily high trend rates (> 35 mm/yr) in the north‒central part of the Southern Patagonian Icefield. These trends have a coherent pattern, motivating a refined viscoelastic glacial isostatic adjustment model to explain the observations. Two end‒member models provide good fits: both require a lithospheric thickness of 36.5 ± 5.3 km. However, one end‒member has a mantle viscosity near η =1.6 ×1018 Pa s and an ice collapse rate from the Little Ice Age (LIA) maximum comparable to a lowest recent estimate of 1995–2012 ice loss at about −11 Gt/yr. In contrast, the other end‒member has much larger viscosity: η = 8.0 ×1018 Pa s, half the post–LIA collapse rate, and a steadily rising loss rate in the twentieth century after AD 1943, reaching −25.9 Gt/yr during 1995–2012.Fil: Lange, H.. Technische Universitaet Dresden; AlemaniaFil: Casassa, G.. Centro de Estudios Cientificos; Chile. Universidad de Magallanes; ChileFil: Ivins, E. R.. Institute of Technology. Jet propulsion Laboratory; Estados UnidosFil: Schroeder, L.. Technische Universitaet Dresden; AlemaniaFil: Fritsche, M.. Technische Universitaet Dresden; AlemaniaFil: Richter, Andreas Jorg. Technische Universitaet Dresden; Alemania. Universidad Nacional de la Plata. Facultad de Ciencias Astronómicas y Geofísicas. Departamento de Astrometría; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaFil: Groh, A.. Technische Universitaet Dresden; AlemaniaFil: Dietrich, R.. Technische Universitaet Dresden; Alemani

Evaluating Models Of The Relationship Between Accounting Profitability Measures And Internal Rate Of Return

Researchers have investigated the relationship between the internal rate of return (IRR) and accounting-based profitability measures using analytical and indirect empirical methodologies.  The current study employs computer simulation to complement the other two methodologies and corroborate their results. The results indicate that the accounting rate of return (ARR) and the conditional estimate of internal rate of return (CIRR) are strongly associated with IRR; however, the length of the estimation period and formulation used for CIRR appear to affect its relationship to IRR.  ARR’s relationship to IRR appears to be unaffected by the length of the estimation period

Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access (R) OV Monitor assay on the UniCel (R) Dxl 800 Immunoassay System

Background: Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer. Methods: The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA125 on the Elecsys System (Roche Diagnostics). Results: Total imprecision (%CV) of the OV Monitor ranged between 3.1% and 8.8%, and inter-laboratory reproducibility between 4.7% and 5.0%. Linearity upon dilution showed a mean recovery of 100% (SD+8.1%). Endogenous interferents had no influence on OV Monitor levels (mean recoveries: hemoglobin 107%, bilirubin 103%, triglycericles 103%). There was no high-dose hook effect up to 27,193 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access OV Monitor and Elecsys CA125 (R = 0.982, slope = 0.921, intercept = + 1.951). OV Monitor serum levels were low in healthy individuals (n = 267, median = 9.7 kU/L, 95th percentile = 30.8 kU/L), higher in individuals with various benign diseases (n = 549, medians = 10.9-16.4 kU/L, 95th percentiles = 44.2-355 kU/L) and even higher in individuals suffering from various cancers (n = 995, medians= 12.4-445 kU/L; 95th percentiles = 53.4-4664 kU/L). Optimal diagnostic accuracy for cancer detection against the relevant benign control group by the OV Monitor was found for ovarian cancer {[}area under the curve (AUC) 0.898]. Results for the reference CA125 assay were comparable (AUC 0.899). Conclusions: The Access OV Monitor provides very good methodological characteristics and demonstrates an excellent analytical and clinical correlation with Elecsys CA125. The best diagnostic accuracy for the OV Monitor was found in ovarian cancer. Our results also suggest a clinical value of the OV Monitor in other cancers

Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients

Background: Patients on long-term hemodialysis are at a significantly higher risk for catheter-related bloodstream infections (BSI) than the general population. These infections are generally caused by Gram-positive organisms, especially Staphylococcus aureus. in the present study, we evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients compared to those causing BSI in other patient populations.Methods: the potencies of daptomycin and various comparator agents were evaluated by reference broth microdilution methods for S. aureus bloodstream isolates from dialysis patients (606 strains) in 43 hospitals in North America and Europe. Susceptibility patterns for the dialysis isolate set were compared to those S. aureus causing BSI in other patient populations in the same hospitals and time period.Results: Daptomycin was highly potent against S. aureus causing bacteremia in dialysis patients (MIC(50)/MIC(90), 0.25/0.5 mu g/ml). Vancomycin (MIC(50)/MIC(90), 1/1 mu g/ml) and linezolid (MIC(50)/MIC(90), 2/2 mu g/ml) showed similar potency, and overall susceptibility rates for the three antibiotics were 99.8-100.0% susceptible. Linezolid and vancomycin were four- to eight-fold less potent than daptomycin.Conclusions: the overall susceptibility patterns of S. aureus strains from dialysis patients were very similar to those of non-dialysis patients. (c) 2008 International Society for Infectious Diseases. Published by Elsevier B.V. All rights reserved.Cubist Pharmaceuticals, Inc.AB BIODISKAbbottAPIArpidaAstellasAstraZenecaAvexaBayerbioMerieuxCadenceCempraCerexaChironCornerstoneCubistDaiichiElanElancoEnantaGlaxoSmithKlineJohnson Et Johnson (Ortho McNeil)MerckNovartisOptimerOrdwayOsmoticsPacific BeachPeninsulaPfizerProtezReplidyneSchering-PloughSequoiaShionogiTheravanceTREK DiagnosticsViroPharmaWyethJMI Labs, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc

Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents

One hundred recent clinical Pseudomonas aeruginosa isolates were used to assess the quantitative (MIC) and qualitative (susceptibility category) accuracies of the MicroScan WalkAway, VITEK, and VITEK 2 automated susceptibility test systems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested. Isolates were selected so that the MICs for the isolates over-represented the MICs near the breakpoints to assess precisely the agreement between the results obtained with the automated systems and the results obtained by the reference tests. the categorical and MIC results from the automated systems were compared to the consensus result of three reference methods: broth microdilution, agar dilution, and disk diffusion. the consensus categorical testing (susceptibility and resistance) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin-tazobactam. All systems tested exhibited a high, unacceptable level of very major (false-susceptible) errors for piperacillin-tazobactam (19 to 27%). Major (false-resistant) error rates were generally acceptable (0 to 3%), but minor error rates were elevated (8 to 32%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent trends toward false resistance. Manufacturer reevaluation of these automated systems for the testing of selected beta-lactams with current clinical isolates of P. aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors.JMI Labs Inc, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, BrazilWeb of Scienc

Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004)

The antimicrobial susceptibility patterns of 9322 contemporary (2002-2004) Gram-positive bacterial isolates collected from 31 medical centres in 14 countries in Europe were evaluated by broth microdilution methods according to CLSI guidelines. the isolates collected comprised Staphylococcus aureus (4842 isolates), coagulase-negative staphylococci (CoNS; 1942 isolates), Enterococcus faecalis (1147 isolates), Enterococcus faecium (391 isolates), beta-haemolytic streptococci (660 isolates) and viridans group streptococci (340 isolates). the organisms were tested against daptomycin and more than 20 comparator agents in Mueller-Hinton broth, supplemented with calcium to 50 mg/L when testing daptomycin. Overall, methicillin (oxacillin) resistance rates were 26.7% and 77.0% for S. aureus (MRSA) and CoNS, respectively, and the vancomycin resistance rate among enterococci was 6.1%. MRSA rates varied from 0.6% in Sweden to 40.2-43.0% in Belgium, Greece, Ireland, the UK and Israel, and VRE rates varied from 0% in Switzerland to 21.2% in Ireland. More than 99.9% of isolates tested were considered susceptible to daptomycin according to breakpoints established by the United States Food and Drug Administration and the CLSI. Daptomycin was active against all Gram-positive species, with the highest MIC being 2, 8, 0.5 and 2 mg/L for staphylococci, enterococci, beta-haemolytic streptococci and viridans group streptococci, respectively. Daptomycin activity was not influenced adversely by resistance to other agents among staphylococci or enterococci. This novel lipopeptide (daptomycin) appears to be an excellent alternative therapeutic option for serious infections caused by multidrug-resistant Gram-positive organisms isolated in Europe.JMI Labs Inc, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc

Potency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates

The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent gram-positive clinical isolates collected in the United States and Europe. Iclaprim demonstrated potent activity against Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. in addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA.Arpida AG (Reinach, Switzerland)JMI Labs, Beaver Kreek Ctr 345, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc